• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BOSTON SCIENTIFIC CORPORATION ELUVIA DRUG-ELUTING VASCULAR STENT SYSTEM; STENT, SUPERFICIAL FEMORAL ARTERY, DRUG-ELUTING

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BOSTON SCIENTIFIC CORPORATION ELUVIA DRUG-ELUTING VASCULAR STENT SYSTEM; STENT, SUPERFICIAL FEMORAL ARTERY, DRUG-ELUTING Back to Search Results
Model Number 24653
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problem Thrombosis (2100)
Event Date 10/30/2018
Event Type  Injury  
Manufacturer Narrative
(b)(6).
 
Event Description
It was reported the patient had recurring stent thrombosis.On (b)(6) 2018, the patient underwent treatment with the eluvia device as part of the (b)(6) clinical trial.The target lesion was located in the right ostial, proximal and mid superficial femoral artery (sfa).The lesion had 5.7mm and 4.1mm reference vessel diameter, proximally and distally respectively.The lesion had a total length of 180mm.The lesion was 100% occluded and was crossed subintimally.Pre-dilataion was performed using five balloons and two 6x120mm eluvia stents were implanted.Two additional non-bsc stents were implanted due to dissection.Post-dilataion was performed using three balloons.Residual stenosis was 25%.On (b)(6) 2018, the patient experienced stent thrombosis.The patient was hospitalized and thrombolysis with alteplase was performed.The patient was discharged on (b)(6) 2018 and the event was assessed as resolved the same day.On (b)(6) 2018, the patient experienced stent thrombosis.The patient was hospitalized and thrombosuction was performed and a stent was placed.The patient was discharged on (b)(6) 2018 "an" the event was assessed as resolved the same day.On (b)(6) 2018, the patient experienced stent thrombosis.The patient was hospitalized and thrombolysis with alteplase was performed.The patient was discharged on (b)(6) 2018 and the event was assessed as resolved as of (b)(6) 2018.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ELUVIA DRUG-ELUTING VASCULAR STENT SYSTEM
Type of Device
STENT, SUPERFICIAL FEMORAL ARTERY, DRUG-ELUTING
Manufacturer (Section D)
BOSTON SCIENTIFIC CORPORATION
two scimed place
maple grove MN 55311
Manufacturer (Section G)
BOSTON SCIENTIFIC IRELAND LIMITED
ballybrit business park
galway
EI  
Manufacturer Contact
sonali arangil
two scimed place
maple grove, MN 55311
6515827403
MDR Report Key8120027
MDR Text Key128899655
Report Number2134265-2018-63342
Device Sequence Number1
Product Code NIU
Combination Product (y/n)N
Reporter Country CodeNL
PMA/PMN Number
P180011
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative,foreig
Reporter Occupation Physician
Type of Report Initial
Report Date 11/30/2018
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received11/30/2018
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Expiration Date06/19/2019
Device Model Number24653
Device Catalogue Number24653
Device Lot Number0021630715
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received11/09/2018
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured12/21/2017
Is the Device Single Use? Yes
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient Age72 YR
-
-